Repeated intravenous thrombolysis in recurrent ischemic stroke within 3 months: a systematic review

Wen, Si-Yuan; Chen, Fei-Fei; Chen, Xiang-Ting; Zhang, Qian; Zhou, Chang-Qing

doi:10.1186/s12883-023-03472-4

BMC Neurology

Table 1 Characteristics of included cases

From: Repeated intravenous thrombolysis in recurrent ischemic stroke within 3 months: a systematic review

Study	No.	Sex	Age	TOAST	Index Stroke						Interval (day)	Recurrent Stroke
Study	No.	Sex	Age	TOAST	Artery	NIHSS	OTT (min)	Drug	sICH	Good outcome	Interval (day)	Artery	NIHSS	OTT (min)	Drug	sICH	Good outcome
Chen et al. [9] 2023	1	F	80	CE	L VA + BA	10	50	alteplase 0.9 mg/kg	NO	YES	9	L VA + BA + PCA	12	140	alteplase 0.6 mg/kg	NO	YES
Černík et al. [10] 2021	2	M	74	LAA	BA	6	35	alteplase 0.9 mg/kg	NO	YES	2	BA + R VA	24	44	alteplase 0.9 mg/kg	NO	NO
Černík et al. [10] 2021	3	M	52	SAO	BA	5	44	alteplase 0.9 mg/kg	NO	YES	11	BA	8	33	alteplase 0.9 mg/kg	NO	YES
Bouchal et al. [11] 2021	4	M	58	LAA	R MCA	13	90	alteplase 0.9 mg/kg	NO	YES*	10	R MCA	14	60	alteplase 0.9 mg/kg	NO	YES
Xiao et al. [12] 2017	5	M	52	LAA	L MCA	14	90	alteplase 0.9 mg/kg	NO	YES*	9	L MCA	12	50	alteplase 0.9 mg/kg	NO	YES*
Laible et al. [13] 2015	6	M	80	CE	BA	19	NR	alteplase 0.9 mg/kg	NO	YES	30	L MCA	18	> 420	alteplase 0.9 mg/kg	NO	NO
	7	F	51	SAO	L MCA	11	350	alteplase 0.9 mg/kg	NO	NO	73	L MCA	14	119	alteplase 0.9 mg/kg	NO	NO
	8	M	48	CE	L MCA	2	NR	alteplase 0.9 mg/kg	NO	YES	66	L MCA	2	220	alteplase 0.9 mg/kg	NO	YES
Mechtouff et al. [14] 2015	9	M	42	LAA	L MCA	6	226	alteplase	NO	YES	14(2nd -3rd)	L MCA	2	150	alteplase	NO	YES
Mechtouff et al. [14] 2015	10	M	42	LAA	L MCA	2	150	alteplase	NO	YES	7(3rd -4th)	L MCA	7	110	alteplase	NO	YES
Qureshi et al. [15] 2015	11	M	73	LAA	NR	NR	NR	alteplase 0.9 mg/kg	NO	YES*	6	R ICA	6	NR	alteplase 0.9 mg/kg	NO	YES
Qureshi et al. [15] 2015	12	M	54	NR	L MCA	NR	NR	alteplase 0.9 mg/kg	NO	YES*	49	L MCA	2	NR	alteplase 0.9 mg/kg	NO	YES
Sposato et al. [16] 2013	13	F	76	CE	R MCA	18	120	alteplase 0.9 mg/kg	NO	YES*	4	L MCA	22	240	alteplase 0.9 mg/kg	YES	NO
Yoo et al. [17] 2013	14	F	73	CE	L MCA	12	70	alteplase 0.9 mg/kg	NO	YES	90	L MCA	12	55	alteplase 0.9 mg/kg	NO	YES
Alhazzaa et al. [18] 2013	15	F	81	CE	R MCA	NR	NR	alteplase 0.9 mg/kg	NO	NO*	6	R MCA	23	NR	alteplase 0.9 mg/kg	YES	NO
	16	M	83	LAA	R MCA	NR	NR	alteplase 0.9 mg/kg	NO	YES*	70	R MCA	9	NR	alteplase 0.9 mg/kg	NO	NO
	17	M	87	LAA	R MCA	NR	NR	alteplase 0.9 mg/kg	NO	YES*	70	R MCA	4	NR	alteplase 0.9 mg/kg	NO	YES
Brigo et al. [19] 2012	18	M	73	SAO	NR	4	240	alteplase 0.9 mg/kg	NO	YES*	2	NR	12	60	alteplase 0.9 mg/kg	NO	YES*
Cappellari et al. [20] 2012	19	F	75	CE	R MCA	4	175	alteplase 0.9 mg/kg	NO	YES*	2	L MCA	15	35	alteplase 0.9 mg/kg	NO	YES*
Nicoli et al. [21] 2011	20	F	77	SVO	R MCA	12	100	alteplase	NO	YES*	7	R MCA	7	95	alteplase	NO	YES*
Nicoli et al. [21] 2011	21	F	77	SVO	R MCA	7	95	alteplase	NO	YES*	10(2nd -3rd)	R MCA	10	105	alteplase	NO	YES*
Sauer et al. [22] 2010	22	F	84	NR	PCA	9	120	alteplase	NO	YES	90	MCA	12	120	alteplase	NO	YES
Smadja et al. [23] 2009	23	M	74	CE	BA	6	240	alteplase 0.9 mg/kg	NO	YES*	0.25	BA	22	60	tenecteplase 0.4 mg/kg	YES	YES*
Topakian et al. [24] 2005	24	M	50	LAA	R MCA	9	120	alteplase 90 mg	NO	YES*	4	R MCA	10	85	alteplase 50 mg	NO	YES

Abbreviations: OTT = onset-to-treatment time; sICH = symptomatic intracranial hemorrhage; NIHSS = National Institute of Health stroke scale; NR = not reported; LAA = large artery atherosclerotic; CE = cardiogenic embolism; SAO = small artery occlusion; L = left; R = right; MCA = middle cerebral artery; PCA = posterior cerebral artery; VA = vertebral artery; BA = basilar artery.
Good clinical outcome: * indicates a decrease in the NIHSS score at discharge ≥ 4 points from the baseline, others indicate the mRS score at 90 days ≤ 2 points after IVT.

Back to article page

ISSN: 1471-2377

Contact us

General enquiries: journalsubmissions@springernature.com